戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 roup (5 vs 11 doses for opioids; 5 vs 10 for nonopioids).
2                                          The nonopioid actions of spinal dynorphin may promote aspect
3 agonism in nociceptors offers a long-awaited nonopioid alternative to systemic antibody NGF sequestra
4 ain, careful monitoring and consideration of nonopioid alternative treatments is warranted.
5 inophen (paracetamol) may represent a viable nonopioid alternative.
6 his perioperative protocol, with emphasis on nonopioid alternatives and patient instructions, may be
7  calculated the frequency of both opioid and nonopioid analgesia administration using complex survey
8  outstanding questions concerning the use of nonopioid analgesia for stronger cancer pain.
9 tant mice also display significantly greater nonopioid analgesia in response to cold water swim stres
10 splant outcomes, present evidence supporting nonopioid analgesia in transplant surgery, and briefly a
11  children requiring postoperative opioid and nonopioid analgesia, and the incidences of postoperative
12  Here, we review the evidence for the use of nonopioid analgesic agents in patients with cancer and d
13 logues stabilized by methylene thioacetal as nonopioid analgesic agents.
14                         At least 2 different nonopioid analgesic drug classes (cyclooxygenase inhibit
15                   Importantly, the number of nonopioid analgesic drug classes administered during sur
16                     Commonly used opioid and nonopioid analgesic drugs produce adverse effects and ar
17 pain, are being replaced by a combination of nonopioid analgesic drugs with diverse modes of action a
18                    Testing of an alternative nonopioid analgesic gene, IL-10, alone or in combination
19 of multimodal pain regimens that incorporate nonopioid analgesic medications to reduce inpatient opio
20          This was accomplished by optimizing nonopioid analgesic medications using a stepped care alg
21    Odontogenic pain can be debilitating, and nonopioid analgesic options are limited.
22 receptor X1 (MrgprX1) represents a promising nonopioid analgesic target because of its selective expr
23 t could be used as scaffold to produce novel nonopioid analgesic therapies and clarifies the molecula
24 se associated with prescription opioids, (2) nonopioid analgesic use should be optimized in the perio
25 a triaminopyridine derivative that acts as a nonopioid analgesic.
26 ions (24.5%), followed by diuretics (22.1%), nonopioid analgesics (15.4%), hypoglycemics (10.9%), and
27 arbiturates (6.3%), benzodiazepines (11.1%), nonopioid analgesics (15.7%), and antihistamines (21.8%)
28      The average +/- SD daily oral intake of nonopioid analgesics (2.6+/-1.4 pills per day) was decre
29                                     Systemic nonopioid analgesics and adjuvant analgesics may be pres
30  is needed to evaluate changes in the use of nonopioid analgesics and alternative pain therapies.
31               Multimodal analgesia including nonopioid analgesics and ambulatory continuous periphera
32                    Consumption of opioid and nonopioid analgesics and evaluation of catheter-associat
33 s promising scaffolds for the development of nonopioid analgesics and immunomodulators, with favorabl
34 or the use of low-dose opioids combined with nonopioid analgesics and in the treatment of opioid use
35  compares prescribing patterns of opioid and nonopioid analgesics and patients' dental pain outcomes
36                                      Because nonopioid analgesics are much sought after, we computati
37 tients from the intervention group requested nonopioid analgesics considerably less often (n = 17 [57
38                           To the extent that nonopioid analgesics reduce opioid consumption, they may
39 estigate beneficial and harmful effects of 4 nonopioid analgesics regimens.
40 ns have the dilemma of prescribing opioid or nonopioid analgesics to chronic pain patients; however,
41 or the use of low-dose opioids combined with nonopioid analgesics to treat pain and opioid use disord
42 last opioid before discharge, and receipt of nonopioid analgesics varied substantially.
43 andout, postdischarge instructions for using nonopioid analgesics, and no routine opioid prescription
44 ons of self-reported prescription opioid and nonopioid analgesics, including nonsteroidal anti-inflam
45  treatment of sickle pain entails the use of nonopioid analgesics, opioid analgesics, and adjuvants s
46 scussed include nonpharmacologic techniques, nonopioid analgesics, opioids, adjuvant medications, rad
47 dalities for chronic somatic pain, including nonopioid analgesics, trigger-point injections, and phys
48 1 (TRPV1) receptor is a promising target for nonopioid analgesics, yet hyperthermic side effects have
49 ombining regional techniques with opioid and nonopioid analgesics.
50  targets that could be used to develop safer nonopioid analgesics.
51 nzodiazepines (PR, 2.01; 95% CI, 1.90-2.13), nonopioid analgesics/anti-inflammatory drugs (PR, 1.88;
52 ndomized 1:1 to receive OA (around-the-clock nonopioids and opioids for breakthrough pain) or OFA (ar
53                                        Early nonopioid bundle administration increased from V1 (aceta
54     Pathway version 3 (n = 240) required the nonopioid bundle as default in the recovery room and sch
55 ug (acetaminophen, celecoxib, methocarbamol) nonopioid bundle, and implemented the 5x-multiplier (las
56 lying cellular mechanisms of nonhormonal and nonopioid CGRP/RAMP1 blockade in a mouse model of endome
57 vely achieved MOH remission in patients with nonopioid CM-MOH within 6 months.
58 reened and 620 participants enrolled (584 in nonopioid cohort and 36 in opioid cohort).
59 t on the commissural/associational system, a nonopioid-containing pathway.
60 ficacy of opioids compared with placebo or a nonopioid control did not show reduced pain with opioids
61 te of alcohol (17.2% vs 2.8%, P < 0.001) and nonopioid drug (2.2% vs 0.2%, P = 0.023) dependence/abus
62 nd stimulant, or (4) all other nonstimulant, nonopioid drugs.
63                                    Among the nonopioid exposed, the adjusted cumulative incidence of
64 nase dependent desensitization of opioid and nonopioid G protein-coupled receptors (GPCRs).
65 MORs results in altered kinase regulation of nonopioid GPCRs after chronic treatment with morphine an
66 meostatic change in the kinase regulation of nonopioid GPCRs could account for the systems level in v
67 main score of 21.5 (17-25) compared with the nonopioid group at 15 (9.8-21, P = .03).
68 ifferences in the neurochemical mediation of nonopioid (i.e., naloxone-insensitive) stress-induced an
69  suggesting that liability likely extends to nonopioid illicit drug dependence.
70 ostoperative pain control was achieved using nonopioid interventions.
71 sms involved in the binding of opioid versus nonopioid ligands.
72  (nAChRs) have been proposed as an important nonopioid mechanism based on studies demonstrating preve
73  (ER), an approved analgesic with opioid and nonopioid mechanisms of action and low abuse potential,
74 consequences of the opioid epidemic, limited nonopioid medication options have been developed to trea
75 opioid policy landscape and other sources of nonopioid medication use.
76 enous fluids and 1 on prescribing opioid and nonopioid medications (counterbalancing measure), over a
77                              Where possible, nonopioid medications and regional anesthetic blockade a
78 FACES scores and decreased use of opioid and nonopioid medications compared with LAI.
79 ids with increasing doses and/or addition of nonopioid medications for breakthrough pain) after posto
80    Both pregabalin and gabapentin are common nonopioid medications used to treat chronic pain, which
81                    Fewer doses of opioid and nonopioid medications were given to the BRSB group compa
82 polypharmacy, healthcare utilization, use of nonopioid medications, and opioid use on and before the
83 ngle-day buprenorphine dosing and adjunctive nonopioid medications, for initiating adults with opioid
84                Sigma receptors (sigmaRs) are nonopioid, nonphencyclidine binding sites with robust ne
85 ay services, home-based palliative care, and nonopioid pain management increased by 4.6, 0.02, 1.1, a
86 study estimates the prevalence of opioid and nonopioid pain management techniques used by US adults w
87 ver support, home-based palliative care, and nonopioid pain management) since 2019.
88 ources, including insufficient research into nonopioid pain management, ethical lapses in corporate m
89    Results of this study showed increases in nonopioid pain medication prescribing after the release
90       Logistic regression models showed that nonopioid pain medication prescribing odds were higher b
91  of this guideline coincided with changes in nonopioid pain medication prescribing rates remains unkn
92       The primary outcome was receipt of any nonopioid pain medication prescriptions (analgesics or a
93 nce), celiac plexus block, splanchnicectomy, nonopioid pain medication, and opioids.
94 stimates remained after accounting for other nonopioid pain medications (MDD OR, 1.14; 95% CI, 1.04-1
95 support the existence of parallel opioid and nonopioid pain modulatory systems and highlight the abil
96 ween preoperative opioid use education about nonopioid pain strategies and duration and quantity of o
97                                    Fusion of nonopioid pharmacophores, such as neurotensin, with opio
98 these outcomes and identify particular prior nonopioid prescriptions, medical history, incarceration,
99                   We observed disparities in nonopioid psychotropic use between black and white women
100 ive medications (opioid pain medications and nonopioid psychotropics, including antidepressants/anxio
101 toxicity with similar efficacy, indicating a nonopioid receptor-mediated effect.
102 ESS could be treated postoperatively using a nonopioid regimen of either acetaminophen alone or aceta
103 95% CI 0.37-0.92; high-quality evidence) and nonopioid (RR 0.52, 95% CI 0.27-0.98; moderate-quality e
104 t of stress-induced analgesia (SIA), whereas nonopioid SIA was not changed.
105 gether, these results define ASIC1a as a new nonopioid target for dynorphin action and suggest that d
106                         Guidelines recommend nonopioid therapies, but the efficacy of mindfulness-bas
107  safer, orally bioavailable MrgprX1 PAM as a nonopioid therapy for neuropathic pain.
108 ng TNFR2 signaling could be developed into a nonopioid therapy for the treatment of chronic neuropath
109                       Of primary importance, nonopioid therapy is preferred for treatment of chronic
110 opioid therapy versus placebo, no opioid, or nonopioid therapy; different opioid dosing strategies; o
111 e pain along with utilization of opioids and nonopioids thus formulating a multimodal approach to pai
112  population included 584 participants in the nonopioid-treated cohort with a mean age of 44 years and
113                  There is an urgent need for nonopioid treatments for chronic and neuropathic pain to
114 ts aimed at delivering safer, more effective nonopioid treatments for neuropathic pain.
115                                              Nonopioid treatments for pain after therapeutic procedur
116 lockade of TLR4/MD2 by administration of the nonopioid, unnatural isomer of naloxone, (+)-naloxone (r
117 igher symptom burden long-term compared with nonopioid users.
118  long-term symptom burden between opioid and nonopioid users.
119                                              Nonopioids were recommended for mild pain, with the addi
120  breakthrough pain) or OFA (around-the-clock nonopioids with increasing doses and/or addition of nono

 
Page Top